Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau

Shanghai 10th People's Hospital86 enrolled

Overview

To test the hypothesis that retinal nerve fiber layer (RNFL) thickness is correlated with Aβ and Tau concentration of cerebrospinal fluid (CSF) in an older population.

retinal nerve fiber layer (RNFL) thickness changing has been reported in Alzheimer's Disease (AD) patients at an early stage, and has been demonstrated as a potential biomarker able to predict cognitive deterioration (Hinton DR et al., N Engl J Med 1986; London A et al. Nat Rev Neurol 2013; Chang LY et al., Alzheimers Dement 2014). However, whether RNFL thickness is correlated with cerebrospinal fluid (CSF) features of AD pathogenesis (e.g., Aβ and Tau) remains unclear. The investigators thus conducted this observational cohort study to test the correlation between RNFL thickness changing and CSF, to further validate RNFL as a potential AD biomarker.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alzheimer Disease

Interventions

surgeryPROCEDURE

All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 50 years old or older; 2. five years or more of education and scores of MMSE ≥ 24 points; 3. Chinese as their first language; 4. Having spinal anesthesia. Exclusion Criteria: 1. prior diagnoses of neurologic diseases, e.g., dementia, Parkinson's diseases, multiple sclerosis or stroke according to DSM-IV; 2. history of mental disorders (e.g., major depressive disorder and schizophrenia) diagnosed according to DSM-IV; 3. known diseases contributing to the retina pathologies, e.g., diabetes, glaucoma or increased intraocular pressure (more than 22 mmHg), cataract, and macular degeneration and hypermyopia; 4. unwillingness to comply with the cognitive assessments; 5. ungradable images of OCT.

Locations (1)

Shanghai 10th People's Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Specific cognitive function

Neuropsychological test battery to assess specific cognitive function, including immediate memory, visuospatial memory and executive function.

Time frame: Within one week before surgery

Secondary Outcomes

retinal nerve fiber layer (RNFL) thickness

Optical coherence tomography (Carl Zeiss Meditec, Inc., Dublin, CA, USA) to measure RNFL thickness

Time frame: Within one week before surgery

Cerebrospinal fluid (CSF) Aβ concentration

ELISA kits (Aβ40: Cat. # 292-62301; Aβ42: Cat. # 296-64401, Wako, Richmond, VA) to measure Aβ concentration

Time frame: During the spinal anesthesia before the administration of the local anesthetic.

Cerebrospinal fluid (CSF) Tau concentration

ELISA kits (Tau: Cat. # KHB0041, Invitrogen, San Francisco, CA) to measure Aβ concentration

Time frame: During the spinal anesthesia before the administration of the local anesthetic.

Global cognitive state

Mini-Mental State Examination (MMSE) to assess global cognitive function

Time frame: Within one week before surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.